메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

워터스, '전하 검출 질량 분석 기술' 출시, 차세대 바이오 치료제 개발 가속

헤드라인 Xevo™ CDMS는 분자량이 크고 이질적인 생체분자에 대해 직접적이고 정확한 질량 검출을 지원. 1 검체당 10분 이내에 바이러스 벡터 캡시드 구분 (Empty, Partial, Full) 및 단백질 복합체, 핵산, 유전자 전달체를 정확하게 분석 가능.2 세포 및 핵산 분석 시, 기존 방법에 비해 최대 100배 적은 검체량으로도 분석 가능.3 밀포드, 매사추세츠주, 2025년 10월 15일 -- 워터스 코퍼레이션(Waters Corporation, NYSE: WAT)이 13일 차세대 치료제와 구조 생물학의 핵심인 광범위한 초대형 생체분자를 탁월하게 측정•특성화 분석할 수 있는 'Waters Xevo 전하 검출 질량 분석기(Charge Detection Mass Spectrometer, 이하 'CDMS')'를 공개했다. 세포 및 유전자 치료제, mRNA, 복합 단백질 치료제의 급속한 성장으로 과학자들은 점점 더 크고 이질적인 약물 치료제를 분석하는 데 상당한 어려움에 직면하고 있다. 하지만 기존의 분석 도구는 아주 작은 차이를 구별해낼 수 있는 능력인 분해능(resolution)뿐만 아니라
- 김갑성 기자
- 2025-10-15 15:20
Sinocare Showcases Its Comprehensive Diabetes Management Solutions at EASD

VIENNA, Oct. 15, 2025 -- The 61st Annual Meeting of the European Association for the Study of Diabetes (EASD 2025) was successfully held in Vienna, Austria. During the conference, Sinocare hosted an international industry symposium and an exclusive networking dinner, fully demonstrating the company's professional expertise in diabetes management. International Experts Applaud iCan CGM's Exceptional Clinical Performance On the opening Monday of EASD 2025 in Vienna, Professor Lori Laffel, Dr. Guido Freckmann, and Professor Julia Mader were invited to share their researches
- 김갑성 기자
- 2025-10-15 14:34
Safex Chemicals India Ltd. Receives Frost & Sullivan's 2025 Global Competitive Strategy Leadership Recognition for Excellence in Crop Protection Chemicals

[ 메디채널 김갑성 기자 ] Safex earns global recognition for its innovation-driven strategy, digital transformation, and customer-centric approach in the evolving crop protection chemicals industry. SAN ANTONIO, Oct. 15, 2025 -- Frost & Sullivan is pleased to announce that Safex Chemicals India Ltd. (Safex) has been recognized with the 2025 Global Competitive Strategy Leadership Recognition in the crop protection chemicals industry for its outstanding achievements in strategic execution, innovation, and sustainable growth. This recognition underscores Safex's leadership in driving measurab
- 김갑성 기자
- 2025-10-15 14:00
At the World Congress of Neurology, WHO Outlines a Global Roadmap to Make Brain Health a Universal Reality

SEOUL, South Korea and LONDON, Oct. 15, 2025 -- Neurological conditions now affect more than 40% of the population—over 3 billion people, according to WHO's Global Status Report on Neurology, released at the World Congress of Neurology (WCN) in Seoul. The report reveals that neurological conditions affect one in three people, with over 80% of the burden in low- and middle-income countries. Despite its prevalence, too few countries have a standalone or integrated policy on neurology, only a minority include neurological services in UHC benefit packages, and workforce shortages remain pr
- 김갑성 기자
- 2025-10-15 13:32
Connect With ASEAN : Quality Choice Cremo Crush

BEIJING, Oct. 13, 2025 -- A report by China Report ASEAN On September 29, the Asia-Pacific Center of the China International Communications Group (CICG) released the episode of its "Connect With ASEAN", titled "Quality Choice, Cremo Crush." https://www.youtube.com/watch?v=ZqbsRQIALU0 In 2018, Yili Group Thailand started operated Cremo Ice Cream, officially entering the Thai market. Since then, it has been awarded the "FDA Quality Award" by the Thai Food and Drug Administration for five consecutive years. By p
- 김갑성 기자
- 2025-10-15 10:12
미국생의학연구협회(NABR), 국제자연보전연맹(IUCN)의 결정에 대한 입장 표명

워싱턴 , 2025년 10월 15일 -- 국제자연보전연맹(IUCN, International Union for Conservation of Nature)이 2025년 10월 9일, 긴꼬리마카크(Long-tailed macaque, 학명: Macaca fascicularis)에 대한 '멸종위기(Endangered)' 등급을 유지하기로 결정했다. 이번 결정은 미국생의학연구협회(National Association for Biomedical Research, NABR)가 2023년에 제기한 이의 신청 이후에 내려진 것이다. NABR는 이 신청에서, IUCN의 평가 근거로 사용된 Hansen 등(Hansen et al.)의 검토 논문이 기존의 과학 데이터를 잘못 해석했다고 주장했다.1 NABR의 관련 청원 내용은 NABR 웹사이트 (www.nabr.org)에서 확인할 수 있다. 한편, 행크 젠킨스(Hank Jenkins) 박사 역시 별도의 청원을 통해 Hansen 등 연구진이 '이해충돌' 문제를 지녔으며, 이에 대한 IUCN의 추가 조사가 필요하다고 주장했다. 현재 이러한 이해충돌이 실제로 존재하는지, 또는 IUCN 검토 보
- 김갑성 기자
- 2025-10-15 09:21
Nona Biosciences Appoints Dr. Di Hong as Chief Executive Officer to Drive Technology Innovation and Strategic Growth

CAMBRIDGE, Mass., Oct. 15, 2025 -- Nona Biosciences ("Nona" or the "Company"), a global biotechnology company providing integrated solutions from "Idea to IND" (I to ITM), today announced the appointment of Dr. Di Hong as Chief Executive Officer (CEO). Dr. Hong will be based in Shanghai and report directly to Dr. Jingsong Wang, Chairman of Nona Biosciences. This milestone reflects a pivotal step in Nona's journey to accelerate innovation in antibody discovery and development. Leveraging its proprietary industry-leading Harbour Mice&re
- 김갑성 기자
- 2025-10-15 08:00
Mabwell Announces Latest Clinical Results of Novel B7-H3-Targeting ADC 7MW3711 to Be Presented at 2025 ESMO Congress

SHANGHAI, Oct. 15, 2025 -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that clinical research results of its novel B7-H3-targeting ADC (R&D code: 7MW3711) for multiple advanced solid tumors, will be presented as a poster at the European Society for Medical Oncology (ESMO) Congress 2025. As of Sep. 15, 2025, 74 patients with advanced solid tumor were enrolled and treated with 7MW3711 in the phase I/II study. Among 54 patients treated at 4.0 mg/kg or above and reaching tumor assessment, 19 partial responses (PRs) or complete resp
- 김갑성 기자
- 2025-10-15 00:00
Benchling Reveals the Next Chapter of R&D at Benchtalk 2025

Benchling AI debuts alongside major new capabilities for antibody discovery, automated data analysis, and development BOSTON, Oct. 14, 2025 -- Benchling today unveiled major new capabilities at Benchtalk, its annual customer conference. These new releases are designed to help biotech companies automate R&D workflows and bring the power of AI into scientists' everyday work. "At Benchling, we are on a mission to unlock the power of biotechnology. Advances in AI will help our customers get life-saving medicines to patients faster," said Sajith Wickramasekara,
- 김갑성 기자
- 2025-10-14 21:14
Co-PSMA trial achieves primary endpoint

SYDNEY, Oct. 14, 2025 -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that the Co-PSMA (NCT06907641)[1] Investigator-Initiated Trial (IIT), led by Prof Louise Emmett at St Vincent's Hospital Sydney, has achieved its primary endpoint with a statistically significant higher number of prostate-specific membrane antigen (PSMA)-positive prostate cancer lesions detected using 64Cu-
- 김갑성 기자
- 2025-10-14 21:03

이전

1 2 3 4 5 6 7 8 9 10

많이 본 기사

최근기사

2025-10-18_SAT

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 10월 18일 18시 00분